Winter 2024 Investor Summit Virtual
Telomere Targeting Immunotherapies for Cancer
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Our mission is to research, develop, and deliver innovative medicines to improve and extend people’s lives with cancer.
MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Investigational drug candidates and research:
THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity (read more about THIO).
Our THIO program drives our development pipeline of second-generation telomere targeting agents.